Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: An uncontrolled, open-label, multicentre study

BMJ Open

Volumn 3, Issue 12, 2013, Pages

  Qiao, Lu Dong ^a   Zheng, Bo ^b   Chen, Shan ^a   Yang, Yong ^c   Zhang, Kai ^b   Guo, Hong Feng ^d   Yang, Bo ^e   Niu, Yuan Jie ^f   Wang, Yi ^g   Shi, Ben Kang ^h   Yang, Wei Min ⁱ   Zhao, Xiao Kun ^j   Gao, Xiao Feng ^k   Chen, Ming ^l  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^d PEKING UNIVERSITY SHOUGANG HOSPITAL   (China)

^e PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^f TIANJIN MEDICAL UNIVERSITY   (China)

^g CHINA MEDICAL UNIVERSITY   (China)

^h SHANDONG UNIVERSITY   (China)

ⁱ Tongji Hospital   (China)

^j CENTRAL SOUTH UNIVERSITY   (China)

^k SECOND MILITARY MEDICAL UNIVERSITY   (China)

^l AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FOSFOMYCIN TROMETAMOL;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; BACKACHE; CYSTITIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MORNING DOSAGE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SINGLE DRUG DOSE; URINALYSIS; URINARY TRACT INFECTION;

EID: 84892378628     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004157     Document Type: Article

References (18)

1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002;113:5S-13S. (Pubitemid 34756640)
2. Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious disease mortality in the United States. JAMA 1996;275:189-93. (Pubitemid 26028558)
3. Wang JQ, Wu XP, Li YJ, et al. Nosocomial infection point-prevalence survey in three consecutive years. Chin J Infect Control 2006;01:19-34.
4. Wang JX, Zhu XL, Yang LY. A nosocomial infection point-prevalence survey: results and analysis. Chin J Nosocomiol 2005;10:1119-20.
5. Schito GC. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents 2003;22:79-83.
6. Qi J, Cheng X. Results analysis of ESBLs-producing E. coli in vitro susceptibility to fosfomycin. China Trop Med 2010;10:734-5.
7. Da PN, Rong M, Yong EL. In vitro antimicrobial activity of fosfomycin against Gram-negative bacilli. Dalian Med Univ 2010;32:577-9.
8. Na YQ, Sun G. Guidelines for diagnosis and treatment of urological diseases in China, 2009. Beijing: People's Health Publishing House, 2009:643-4.
9. Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997;53:637-56. (Pubitemid 27145957)
10. Grabe M, Bjerklund-Johansen TE, Botto H, et al. European Association of Urology, Guidelines on Urological Infections. 2010. http://www.uroweb.org/
11. Stein GE. Single-dose treatment of acute cystitis with fosfomycin tromethamine. Ann Pharmacother 1998;32:215-19. (Pubitemid 28082335)
12. Qiao LD, Chen S. Analysis of risk factors about ESBLs-producing E. coli urinary tract infection. J Hosp Infect 2011;21:247-9.
13. Kong HS, Wang BG. Comparative study of antibiotic resistance in clinical isolates of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta lactamases. J Lab Med 2000;23:23-5.
14. Gao L, Xiao YH. 2006-2007 Mohnarin report: bacterial distribution and resistance in urinary tract infections. Chin J Antibiot 2008;33:586-91.
15. Chen H, Liu Y. Relationship between antimicrobial treatment and imbalance of intestinal flora in the elders. Pract Clin Med 2007;9:34-6.
16. Pullukcu H, Aydemir S, Tasbakan M, et al. Is there a rise in resistance rates to fosfomycin and other commonly used antibiotics in Escherichia coli-mediated urinary tract infections? A perspective for 2004-2011. Turk J Med Sci 2013;43:537-41.
17. Pullukcu H, Tasbakan M, Sipahi OR, et al. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007;29:62-5. (Pubitemid 44959781)
18. Naber KG. Fosfomycin trometamol in treatment of uncomplicated lower urinary tract infections in adult women-an overview. Infection 1992;20:S310-12. (Pubitemid 23081502)